Targeting Inflammasomes in Substance Abuse and HIV (R01 Clinical Trial Not Allowed)
Funding Opportunity RFA-DA-19-039 from the NIH Guide for Grants and Contracts. Neuroinflammation triggered by brain trauma, neurodegenerative diseases and neurotoxicant-induced CNS disorders initiates CNS innate immune responses that activate inflammasomes. Inflammasomes are high molecular weight complexes in the cytosol of stimulated immune cells that mediate the activation of inflammatory cascades. In response to insults, Nod-like receptors (NLRs) recruit adaptor proteins and caspase-1 to assemble inflammasomes and process the release of pro-inflammatory cytokines IL-1?, IL-18 and IL-33. Recent evidence suggests that ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - April 4, 2019 Category: Research Source Type: funding
Development of Opioid and Adjuvant Fixed Combination Dosage Forms for the Treatment of Chronic Pain with Reduced Addiction Potential (R41/R42)
Funding Opportunity Number: PA-13-388 Opportunity Category: DiscretionaryFunding Instrument Type: GrantCategory of Funding Activity: EducationHealthCFDA Number: 93.279Eligible Applicants Small businessesAgency Name: HHS-NIH11Closing Date: Jan 07, 2017Award Ceiling: Expected Number of Awards: Creation Date: Nov 07, 2013Funding Opportunity Description: The purpose of this announcement is to fund meritorious applications from small business organizations that aim to develop of opioid and adjuvant drug combinations within a single dosage form for treatment of a pain condition. The drug ...
Source: Grants.gov - November 10, 2013 Category: Research Tags: Education Health Source Type: funding
Development of Opioid and Adjuvant Fixed Combination Dosage Forms for the Treatment of Chronic Pain with Reduced Addiction Potential (R43/R44)
Funding Opportunity Number: PA-13-387 Opportunity Category: DiscretionaryFunding Instrument Type: GrantCategory of Funding Activity: EducationHealthCFDA Number: 93.279Eligible Applicants Small businessesAgency Name: HHS-NIH11Closing Date: Jan 07, 2017Award Ceiling: Expected Number of Awards: Creation Date: Nov 07, 2013Funding Opportunity Description: The purpose of this announcement is to fund meritorious applications from small business organizations that aim to develop of opioid and adjuvant drug combinations within a single dosage form for treatment of a pain condition. The drug ...
Source: Grants.gov - November 10, 2013 Category: Research Tags: Education Health Source Type: funding
Development of Opioid and Adjuvant Fixed Combination Dosage Forms for the Treatment of Chronic Pain with Reduced Addiction Potential (R43/R44)
Funding Opportunity PA-13-387 from the NIH Guide for Grants and Contracts. The purpose of this announcement is to fund meritorious applications from small business organizations that aim to develop of opioid and adjuvant drug combinations within a single dosage form for treatment of a pain condition. The drug combination should provide improved analgesia when compared with the same dose (morphine equivalents) of opioid monotherapy. Such dosage forms should minimize opioid exposure while optimizing analgesia, in order to reduce risk of addiction and limit severity of other opiate adverse effects. (Source: NIH Funding ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 7, 2013 Category: Research Source Type: funding
Development of Opioid and Adjuvant Fixed Combination Dosage Forms for the Treatment of Chronic Pain with Reduced Addiction Potential (R41/R42)
Funding Opportunity PA-13-388 from the NIH Guide for Grants and Contracts. The purpose of this announcement is to fund meritorious applications from small business organizations that aim to develop of opioid and adjuvant drug combinations within a single dosage form for treatment of a pain condition. The drug combination should provide improved analgesia when compared with the same dose (morphine equivalents) of opioid monotherapy. Such dosage forms should minimize opioid exposure while optimizing analgesia, in order to reduce risk of addiction and limit severity of other opiate adverse effects. (Source: NIH Funding ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 7, 2013 Category: Research Source Type: funding
